HETEROCYCLIC COMPOUNDS AS STING AGONISTS

The disclosure relates to a compound represented by Formula 1, or a pharmaceutically acceptable salt thereof, as a stimulator of interferon genes (STING) agonist, pharmaceutical compositions comprising the same, and related methods of and uses in treatment or prevention of disease. L'invention...

Full description

Saved in:
Bibliographic Details
Main Authors KIM, Sung Min, PARK, Yun-Hee, KIM, Cheol Eui, HAN, Nara, JUNG, Yeong Hun, SON, Eun Ji, CHUNG, Chul-Woong, KIM, Ji Soo, LEE, Kun Jung, LEE, Eun Hye, LIM, So Yeon, SONG, Ho Young, LEE, Youg Cheol
Format Patent
LanguageEnglish
French
Published 16.05.2024
Subjects
CHEMISTRY
DERIVATIVES THEREOF
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
NUCLEIC ACIDS
NUCLEOSIDES
NUCLEOTIDES
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SUGARS
Online AccessGet full text

Cover

More Information
Summary:The disclosure relates to a compound represented by Formula 1, or a pharmaceutically acceptable salt thereof, as a stimulator of interferon genes (STING) agonist, pharmaceutical compositions comprising the same, and related methods of and uses in treatment or prevention of disease. L'invention concerne un composé représenté par la formule 1, ou un sel pharmaceutiquement acceptable de celui-ci, en tant qu'agoniste de STING (stimulateur de gènes d'interféron), des compositions pharmaceutiques le comprenant, ainsi que des méthodes et des utilisations associées pour le traitement ou la prévention d'une maladie.
Bibliography:Application Number: WO2023IB00678